Angelo Gardellini

Como, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology

Published: November 13, 2025

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Journal: Cancer

Published: October 24, 2024

Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: Global implications.

Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: Global implications.

Journal: Hematological oncology

Published: August 09, 2024

Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy.

Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy.

Journal: Acta haematologica

Published: April 28, 2024

Lichen planopilaris-like eruption in chronic myeloid leukemia patient during treatment with nilotinib as second-line therapy.

Lichen planopilaris-like eruption in chronic myeloid leukemia patient during treatment with nilotinib as second-line therapy.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: January 17, 2022

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy.

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy.

Journal: Pharmacogenomics and personalized medicine

Published: October 28, 2021

Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.

Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.

Journal: Blood cells, molecules & diseases

Published: October 05, 2021

Severe immune thrombocytopenia after COVID-19 vaccination: Report of four cases and review of the literature.

Severe immune thrombocytopenia after COVID-19 vaccination: Report of four cases and review of the literature.

Journal: Blood cells, molecules & diseases

Published: September 30, 2021

Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy.

Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy.

Journal: Vaccines

Published: May 01, 2021

The first case of Mycobacterium vaccae sepsis in a non-Hodgkin lymphoma patient: biological understandings and clinical consequencies.

The first case of Mycobacterium vaccae sepsis in a non-Hodgkin lymphoma patient: biological understandings and clinical consequencies.

Journal: Access microbiology

Published: April 04, 2020

Autoimmune pancytopenia following chronic immune thrombocytopenia: Case report and literature review.

Autoimmune pancytopenia following chronic immune thrombocytopenia: Case report and literature review.

Journal: Blood cells, molecules & diseases

Published: March 27, 2020

Concurrent chronic myeloid leukemia and CALR-mutated chronic myeloproliferative neoplasm.

Concurrent chronic myeloid leukemia and CALR-mutated chronic myeloproliferative neoplasm.

Journal: Blood cells, molecules & diseases

Published: November 26, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026